Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Chrysomycin B

Chrysomycin B (Synonyms: Albacarcin M, Virenomycin M)

Katalog-Nr.GC18344

Chrysomycin B ist ein aus einem Streptomyces-Stamm isoliertes Antibiotikum. Chrysomycin B verursacht DNA-SchÄden in der Zelllinie des menschlichen Lungenadenokarzinoms A549 und hemmt die Topoisomerase II. Chrysomycin B unterdrÜckt das Wachstum von transplantierbaren Tumoren bei MÄusen.

Products are for research use only. Not for human use. We do not sell to patients.

Chrysomycin B Chemische Struktur

Cas No.: 83852-56-6

Größe Preis Lagerbestand Menge
250μg
234,00 $
Auf Lager
1mg
556,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. It differs from its analog chrysomycin A by having a methyl, rather than vinyl, group in the 8-position of the chromophore. Like its analog, chrysomycin B suppresses the growth of transplantable tumors in mice, an effect that may be related to its ability to bind DNA. It also causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B is structurally very similar to gilvocarcin V, which promotes DNA cross-linking with histone 3 and GRP78 when photoactivated by near-UV light.

Bewertungen

Review for Chrysomycin B

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Chrysomycin B

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.